Patterns of cervical and masticatory impairment in subgroups of people with temporomandibular disorders–an explorative approach based on factor analysis by Ballenberger, N. et al.
Patterns of Cervical and Masticatory Impairment in Subgroups of People 1 
with Temporomandibular Disorders–an Explorative Approach Based on 2 
Factor Analysis 3 
4 
This is the Accepted Manuscript version of: Ballenberger, N. and von Piekartz, H. and Danzeisen, M. and Hall, T. 2017. Patterns 
of cervical and masticatory impairment in subgroups of people with temporomandibular disorders–an explorative approach 
based on factor analysis. Cranio. DOI: 10.1080/08869634.2017.1297904.
Patterns of Cervical and Masticatory Impairment in Subgroups of People 5 
with Temporomandibular Disorders–an Explorative Approach Based on 6 
Factor Analysis 7 
Abstract 8 
Objectives 9 
To identify clinical patterns of impairment affecting the cervical spine and masticatory 10 
systems in different subcategories of TMD by an explorative data driven approach. 11 
Methods 12 
For this observational study 144 subjects were subdivided according to Research 13 
Diagnostic Criteria  for Temporomandibular Disorders into: healthy controls, 14 
temporomandibular joint (TMJ) signs without symptoms, TMJ affected, 15 
temporomandibular muscles affected, or TMJ and muscles affected. Factor analysis was 16 
applied to cervical spine and masticatory data while linear regression was applied to 17 
characterize clinical patterns in subgroups. 18 
Results 19 
Factor analysis identified five clinical dimensions which explained 59% of all variance: 20 
mechanosensitivity, cervical movement, cervical and masticatory dysfunction, jaw 21 
movement, and upper cervical movement. Regression analysis identified different 22 
clinical dimensions in each TMD subgroup. 23 
Conclusion 24 
Distinct clinical patterns of cervical spine and masticatory function were found among 25 
subgroups of TMD, which has clinical implications for therapeutic management. 26 
Factor analysis, subgroup, TMD, cervical, explorative  27 
Introduction 28 
Temporomandibular disorder (TMD) is an umbrella term for structural and functional 29 
disorders related to the masticatory muscles and/or the temporomandibular joint 30 
(TMJ) with or without clinical signs and symptoms (1). It is the second most common 31 
cause of orofacial pain following dental pain (2). The prevalence of signs and 32 
symptoms related to TMD ranges widely, reported as low as 1% and as high as 75%, 33 
affecting more women and younger people which is uncommon for chronic pain 34 
conditions (2–6). The inconsistent epidemiological data is assumed to be a result of 35 
different unstandardized and heterogeneous diagnostic criteria used in the studies to 36 
define TMD and its symptoms (2, 7). The major clinical signs and symptoms associated 37 
with TMD are pain both local and referred into the temporal region of the head, lower 38 
face  and neck, as well as clicking sound’s, reduced and painful mouth opening, and 39 
bruxism (8–10). However, not all individuals diagnosed with TMD have symptoms (11) 40 
and thus it is estimated that only 3% of people with signs of TMD seek medical aid 41 
(10).  42 
Biological as well as psychological aspects  are assumed to be factors in the 43 
development of TMD (12). As a consequence, according to Research Diagnostic 44 
Criteria/TMD (RDC/TMD), classification of TMD will include  physical or psychological 45 
diagnoses. Under physical diagnosis, patients are classified into muscle disorders 46 
and/or disc displacements and/or arthralgia, osteoarthritis or osteoarthrosis (1, 6, 13). 47 
The importance of diagnosis is to identify the appropriate management strategy from 48 
the broad spectrum of therapies described for this condition. 49 
Within the contributing factors to TMD the cervical spine is considered to play a crucial 50 
role (14). Studies show anatomical and pathophysiological interactions between the 51 
cervical spine and TMJ region (15–21). For example, people with TMD show higher 52 
prevalence and one-year-incidence for neck pain than those without TMD  (20, 22). 53 
Furthermore, it has been demonstrated that the neck disability index is  highly 54 
correlated with the jaw function scale (23). Studies have also demonstrated the 55 
influence of various head and neck postures on the masticatory muscles and their 56 
mechanosensitivity (18, 24). Additionally, there is some evidence that cervical 57 
dysfunction is the consequence of TMD. As such, various authors describe a positive 58 
effect of orofacial therapy (21, 25) on the function of the cervical spine. Yet, a clear 59 
causal relationship remains unclear.  60 
Despite this, there is little high quality research evidence that has investigated the 61 
relationship between cervical dysfunction and TMD. Furthermore, according to the 62 
author´s knowledge, there are no studies investigating whether subgroups of TMD 63 
show distinct patterns of cervical and masticatory impairment. Finally, studies are 64 
lacking that give a comprehensive picture of the interaction between the cervical spine 65 
and the TMJ. 66 
Consequently, the aim of this study is to describe and perform an extensive analysis in 67 
a study sample consisting of individuals classified into five subgroups according to 68 
physical diagnostic criteria of RDC/TMD. Subgroups of TMD are characterized with 69 
respect to patterns of impairment based on clinical and functional measurements 70 
associated with the masticatory and cervical systems. Therefore, instead of testing 71 
predefined, clinically driven hypotheses (which is the common way), this study uses an 72 
explorative data driven approach based on factor analysis. More detailed knowledge of 73 
clinical patterns of cervical and masticatory impairment among subgroups of TMD may 74 
ultimately direct management and thereby improve therapeutic outcomes.    75 
Methods 76 
Participants 77 
For this observational study, subjects were recruited from physiotherapy practices in 78 
Northern Germany by information flyers. Subjects were evaluated for inclusion by a 79 
clinical expert with 15 years of experience managing orofacial pain according to the 80 
following criteria: (1) age at least 18 years, (2) score of less than 3 on the modified 81 
Chronic Grade Pain Scale (26–29) indicating chronic condition status , (3) conversant in 82 
the German language, (4) score of more than 3 measured on the CONTI questionnaire 83 
suggesting evidence of TMD  (30).  84 
Subjects acting as controls were selected from the same environment if they met the 85 
following criteria: (1) age at least 18 years, (2) conversant in the German language, (3) 86 
score of ≤ 3 measured by the CONTI questionnaire. Subjects were excluded if they had 87 
(1) a history of surgery or fractures in the neck and jaw or (2) neurologic deficits or (3) 88 
pain at night or other red flags or (4) were currently undergoing orthodontic 89 
treatment. Prior to participation, subjects gave written informed consent. The study 90 
was conducted in accordance with the Declaration of Helsinki and was approved by 91 
the local ethics committee of the University of Applied Science Of Osnabrück.  92 
For further stratification subjects were subdivided according to RDC/TMD. Therefore 93 
the presence of painful and restricted mouth opening, painful masticatory muscles on 94 
palpation, and TMJ sounds were assessed. These criteria are designed to define the 95 
subgroup of TMD. (31). As a consequence, patients with TMD (CONTI > 3) were 96 
subdivided into group “Arthogen” when joint disorders were present, group ”Myogen” 97 
when myofascial disorders were present, or into group “Mixed” when both joint 98 
disorders and myofascial disorders were present. Subjects acting as controls (CONTI ≤ 99 
3) were subdivided into group “Controls” having no TMD signs or pain or group “Just 100 
signs” having TMD signs that are not clinically relevant based on the Conti scale (30). 101 
Consequently, five subgroups were investigated with different diagnoses of TMD. We 102 
proposed that the “Mixed“ group would be the most severe as they had both joint 103 
disorders and myofascial involvement.  104 
Functional measurements  105 
The TMJ and the cervical spine were examined and measured separately by two 106 
clinically experienced physiotherapists who had 8 hours intensive training in the 107 
management of orofacial disorders. The investigator who executed the neck 108 
measurements was blind to subjects TMD subgroup classification.  109 
TMJ Region 110 
Range of motion 111 
Measurements of TMJ range of motion (ROM) included mouth opening, active lateral 112 
shift of the jaw to both sides as well as active backward and forward movement of the 113 
jaw. Inter- and Intra-rater reliability has been shown to be moderate to excellent for 114 
these measurements. 115 
Mechanonsensitivity 116 
Mechanosensitivity of the Masseter and Temporalis muscles was determined by 117 
measuring pressure pain threshold (PPT) using an algometer (Wagner instruments, 118 
Force dial FDK 10). Pressure was applied at a constant rate of approximately 1 119 
kg/cm2/s until subjects reported the point when the sensation changed from pressure 120 
to pain. Two readings were taken over each site and each muscle and averaged for 121 
analysis. PPT has been shown to be a valid and reliable method for measuring 122 
mechanosensitivity (32–34).  123 
CONTI 124 
The Conti questionnaire (30) was used for assessing TMD symptoms. This scale 125 
comprises ten questions concerning typical TMD features and has a score from 0, 126 
indicating no clinically relevant TMD, to 23. Prior to the examination subjects were 127 
asked whether they suffered from pain in the masticatory and cervical region. 128 
PAIN 129 
Pain was graded according to the Colored Analogue Scale (CAS) from 0 to 10. The CAS 130 
has high reproducibility (35). 131 
Cervical spine  132 
ROM 133 
Active cervical ROM in all planes (flexion, extension, lateral flexion, and rotation) was 134 
measured by the Cervical ROM (CROM) device (36, 37). Maximum angles within 135 
comfortable limits were recorded. The CROM device is described as valid and reliable 136 
(36, 38, 39).  137 
Mechanosensitivity 138 
Mechanosensitivity of Upper Trapezius and Obliquus Capitis Inferior muscles were 139 
determined by measuring PPT using the method described above. 140 
Neck disability index  141 
The Neck disability index (NDI) was used to assess neck related disability and 142 
comprises 10 self-report questions covering activities of daily living, concentration and 143 
pain. The scale ranges from 0 (no pain and disability) to 50 (severe pain and disability) 144 
and has been shown to have good to excellent psychometric properties (40, 41).  145 
Flexion-Rotation Test 146 
Upper cervical rotation in end-range flexion (FRT) (42, 43) was recorded using a digital 147 
goniometer (Halo Medical Device), while pain during the FRT was recorded by the CAS. 148 
Cranio-cervical Flexion-Test  149 
The Cranio-cervical Flexion-Test (CCFT) was used to measure endurance of the cervical 150 
deep flexor muscles (44, 45) evaluated using a pressure biofeedback device 151 
(Chattanooga, USA) according to a reliable procedure described by Hudswell (46–48).  152 
Number of cervical signs 153 
Palpation of the three upper cervical spine motion segments was conducted to assess 154 
segmental mobility and pain. The number of symptomatic findings were aggregated 155 
and termed “cervical signs”. This procedure has good reliability (49).  156 
All measurements are summarized in Table S1 available online.   157 
Analysis 158 
All statistical analysis was performed with R (50) including the psych package (51). 159 
Analysis of variance and chi2 was used to test for differences in baseline characteristics 160 
between subgroups of participants. P-values < 0.05 were considered significant. The 161 
basis of our analysis strategy was as follows: Rather than confirming whether clinically 162 
driven predefined clinical patterns are present among subjects with TMD, we 163 
performed a data driven explorative analysis strategy in order to identify clinically 164 
relevant patterns among subgroups of individuals with TMD. Therefore we conducted 165 
five steps including factor analysis and linear regression analysis. 166 
Step 1: Factor analysis was used as a dimension reduction method. Measured variables 167 
were condensed to a reduced number of factors that would still contain the majority 168 
of the information from the original data. The dimensionality of the data was assessed, 169 
where each factor represents a clinical dimension which was characterized with 170 
respect to a clinical meaning. The appropriate number of relevant clinical dimensions 171 
was established by applying the Very Structure Criterion (52) and the Parallel Analysis 172 
Criterion (53) as implemented in the psychological package. Where inconsistency of 173 
the statistical solutions was detected the more interpretable solution with respect to 174 
clinical meaning was selected. The amount of information (variance) that is captured 175 
by each of extracted factors was calculated by determining their eigenvalues.  176 
Step 2: graphical descriptive means were used to assess the ability of the data to 177 
discriminate people with TMD from controls in general. A scatterplot representing 178 
each individual´s score for each pair of factors was constructed demonstrating the 179 
general clinical relevance of the identified dimensions. 180 
Step 3: the extracted factors (clinical dimensions), were interpreted with respect to a 181 
clinical and functional meaning.  Therefore, all measured variables were correlated 182 
with the extracted factors. Their correlation coefficients represent their loadings on 183 
the factors.  By inspecting the correlation coefficients of each measured variable with 184 
each factor the contribution of each variable to the respective factor was evaluated. As 185 
a consequence, the clinical meaning of the factors was interpreted. In order to 186 
facilitate interpretation, the factor solution was rotated before calculating the 187 
correlation structure, in our case by Varimax rotation.  Conceptually, the factors have 188 
the function of summary variables of the underlying clinical dimension. The score of 189 
each individual on each factor was calculated. As a consequence, it was possible to 190 
quantify each person´s score on the respective clinical dimension, i.e. a low/high 191 
person´s score represents a low/high summary score of the respective clinical 192 
dimension.  193 
Step 4: subgroup characterization was performed with respect to the clinical 194 
dimensions. Therefore, we aimed to determine to what extent each of the TMD 195 
subgroups was affected with respect to the respective clinical dimension. To do so we 196 
conducted the analysis with both the extracted factors, representing the clinical 197 
dimensions as summary variables, and with the original variables contributing to the 198 
respective clinical dimensions. For this purpose we used linear regression with 199 
subgroup membership as independent variables and all variables standardized 200 
(Mean=0, SD=1). Results are given as standardized mean differences and interpreted 201 
as effect sizes according to Cohen (<0.2 no effect, 0.2-0.5 small effect, 0.5-0.8 202 
moderate, 0.8>large effect) (56).  This approach is analogous to meta- analysis in order 203 
to be able to compare results across outcomes with different units.   204 
Step 5: Finally, a summary was generated of how the TMD subgroups were 205 
characterized with respect to the identified clinical dimensions. Also, here the strength 206 
of clinical impairment in each dimension was given as interpretable values according to 207 
Cohen. Hence, the clinical pattern of each subgroup was presented indicating which 208 
clinical dimension was affected to which extent. 209 
The quality of the factor analysis models was assessed using Bartlett’s test for 210 
sphericity (54) and the Kaiser-Meyer-Olkin test (55). For regression analysis, variables 211 
that assessed bilateral measurements were combined to one variable by calculating 212 
the mean of left and right sides as no significant side differences were present. 213 
Additionally, we added age and gender as covariates into regression models as 214 
potential confounders. If p-values of confounders according to t-statistics were >0.1, or 215 
changed the estimate less than 10%, those variables were withdrawn from the model.  216 
Results 217 
Of 175 people assessed for inclusion 144 participants met the study criteria. These 218 
people were divided into five subgroups and characterized with respect to clinical 219 
patterns of impairment based on clinical and functional measurements from the TMJ 220 
and cervical spine as depicted in the work flow diagram in Figure 1. 221 
Figure 1: 222 
Baseline characteristics are summarized in Table 1.  223 
Bartlett’s Test of Sphericity was highly significant (Chi square = 1513.003, P < 0.001) 224 
and the KMO test was 0.82, supporting the suitability of the data for factor analysis. 225 
Step 1 clinical dimensionality of data: We extracted 5 independent factors by factor 226 
analysis representing five clinical dimensions. In total, the five dimensions explained 227 
59% of the total variance (dimension 1 - 23%, dimension 2 - 13%, dimension 3 - 8%, 228 
dimension 4 - 8%, and dimension 5 - 5%).   229 
Step 2 general overview of distinction between subjects with TMD and controls: Figure 230 
2 shows the scores of all individuals on each of the five factors, i.e. on each clinical 231 
dimension. Each scatter plot shows each individual´s score of a pair of dimensions. E.g. 232 
the very left top plot depicts scores of dimension 1 on the x-axis and scores of 233 
dimension 2 on the y-axis. Black Cs represent the control group including the control 234 
group with symptoms of TMD. Grey Ts represent the TMD group including sub-groups 235 
“Arthrogen“, “Myogen“ and “Mixed“. Plots of dimension 1 to dimension 4 show, albeit 236 
some overlap of the dots, that the scores of subjects with TMD are separate to the 237 
scores of controls indicating that subjects with TMD generally possess distinct 238 
underlying clinical patterns compared to controls. This especially holds true for the 239 
third dimension. Factor 5 suggests no distinct pattern between the groups.  240 
Figure 2:  241 
Step 3 Characterization of clinical dimensions. In Table 2 the factor loadings of each 242 
measured variable are listed. The key variables of each independent factor, i.e. clinical 243 
dimension, are marked in grey. The values are the correlation coefficients of each 244 
measured variable with each factor. This allows the clinical and functional 245 
interpretation of the clinical dimensions. As a consequence, factor 1 represents the 246 
clinical dimension “mechanosensitivity” as it includes all variables measuring 247 
mechanosensitivity of muscle sites in the masticatory and cervical region as well as the 248 
variable “cervical signs” (coefficient range: 0.64-0.89). Factor 2 is characterized by the 249 
clinical dimension cervical ROM which includes movement in all directions (coefficient 250 
range: 0.54-0.81). Factor 3 comprises both cervical and masticatory dysfunction 251 
measured by the NDI and CONTI questionnaires, as well as the presence of pain when 252 
performing the FRT (coefficient range: 0.47-0.72). As a consequence we called this 253 
clinical dimension “Cervical/masticatory dysfunction and pain”. Factor 4 represents the 254 
clinical dimension “jaw movements” which includes TMJ movement in all directions 255 
(coefficient range: 0.43-0.7). The last factor consists of the clinical dimension FRT ROM 256 
and the CCFT (coefficient range: 0.45-0.78).  257 
Table 2:  258 
Step 4 Characterization of TMD subgroups: Figure 3 shows the pairwise differences 259 
between each of the subgroups compared to the Control group with respect to all 260 
clinical dimensions including all contributing variables. Linear regression was used for 261 
this analysis. The first variable of each column and each pairwise comparison 262 
(summary variable) represents the extracted factors by factor analysis and is 263 
considered as the summary variable of each corresponding clinical dimension for the 264 
respective group comparison. Below each summary variable the contributing variables 265 
to each clinical dimension, according to Table 2, are listed. The effects of the 266 
subgroups “Mixed”, “Myogen”, “Arthrogen“ and “Just signs” in comparison to the 267 
reference group (control group without TMD signs) are presented as standardized 268 
mean differences (SMD) and ±95% Confidence Intervals. It allows interpretation of the 269 
coefficients in effect size. In the dimension “mechanosensitivity” the overall effect size 270 
represented by its summary variable for the comparison “Mixed” group vs control 271 
group is -0.83 [-1.32;-0.38] suggesting a large effect. In others words this means that in 272 
general, mechanosensitivity of the “Mixed“ group is greatly elevated when compared 273 
to “Controls“. This effect is consistent across all single variables of the clinical 274 
dimension “mechanosensitivity”. The variables range from -0.77 for Temporalis muscle 275 
to 0.92 for “cervical signs”. The second largest effect size with respect to the clinical 276 
dimension “mechanosensitivity” is observed between the “Myogen“ group and the 277 
control group with an effect size of -0.39 [-0.96;0.21]. In the remaining two groups the 278 
effect size is below -0.25.  For the dimension “cervical mobility” a similar pattern is 279 
observed. Also here the “Mixed“ group has the most reduced cervical ROM with an 280 
effect size of -0.58 [-1.06;-0.10] followed by the “Myogen“ group having an effect size 281 
of -0.38 [-0.99;0.23]. The most affected direction in both the “Mixed“ and “Myogen“ 282 
group is extension with effect sizes of -0.69 [-1.16;-0.23] and -0.63 [-1.19;-0.06] 283 
respectively. The least affected variable in both groups is flexion (effect size in the 284 
“Mixed“ group: -0.27[-0.78;0.24], effect size in the “Myogen“ group: -0.36 [-285 
0.98;0.26]). 286 
Dimension  “Cervical/masticatory dysfunction and pain”, is similarly impaired in all 287 
subgroups apart from “Just signs” group. The large effect sizes of the summary 288 
variables range from -0.94[-0.50;-1.38] in the “Mixed“ group to -1.28 [-0.72;-1.83] in 289 
the “Myogen“ group. The effect sizes for the single variables CONTI, NDI and pain 290 
during FRT range in the three affected subgroups between -0.78 [-0.33;1.20] and -1.69 291 
[-1.35;-2.04]. Acute pain is only present in the “Myogen“ group with an moderate 292 
effect size of -0.71 [-0.27;-1.15]. Dimension 4 ”jaw movement” is restricted across all 293 
subgroups with moderate effects sizes of the summary variables from -0.54 [-294 
1.15;0.08] in the “Myogen“ group to -0.77[-1.27;-0.26] in the “Mixed“ group. Finally, 295 
the last dimension has no clinical meaning for any of the subgroups indicated by effect 296 
sizes lower than 0.20.  297 
Figure 3:  298 
Step 5 summary of clinical patterns in TMD subgroups:  299 
In Table 3 the clinical patterns with respect to the cervical and masticatory systems of 300 
the subgroups are depicted. Arrows indicate to which extent a subgroup is restricted in 301 
each clinical dimension and represent effect sizes stemming from the summary 302 
variables of each clinical dimension shown in figure 3. One arrow is a small effect, two 303 
arrows a medium effect and three arrows a large effect. As a consequence, the 304 
“Mixed“ group is the most affected group, with moderate to large limitations in the 305 
dimensions “mechanosensitivity”, “cervical ROM”, “cervical and masticatory 306 
dysfunction and pain” and “jaw movement”. The “Myogen“ group is also affected in 307 
the same dimensions, however, less with respect to “mechanosensitivity” and “cervical 308 
ROM”. Groups “Arthrogen“ and “Just signs“ have only medium to large limitations in 309 
dimensions “cervical and masticatory dysfunction and pain” and jaw movement.  310 
Table 3:  311 
Discussion 312 
In this explorative data driven analysis five independent clinical dimensions were 313 
identified based on 28 functional measurements from the cervical spine and 314 
masticatory systems using factor analysis with varimax rotation and linear regression 315 
analysis. These dimensions are interpreted as mechanosensitivity, cervical ROM, 316 
cervical and masticatory dysfunction, jaw movement and upper cervical 317 
ROM/endurance. The five factors explain 59% of all variance. Furthermore, the 144 318 
subjects divided into five subgroups according to RDC/TMD were characterized with 319 
respect to the five clinical dimensions. The “Mixed“ group is the most affected group 320 
with moderate to large limitations in all dimensions followed by the “Myogen“ group 321 
with limitations in the same dimensions, however, less with respect to 322 
mechanosensitivity and cervical ROM. Groups “Arthrogen“ and “Just signs“ show 323 
medium to large limitations only concerning cervical and masticatory dysfunction and 324 
jaw movement. A clear dose response relationship was observed indicating that 325 
subjects with a diagnosis of TMD in two aspects (myogenic and arthrogenic) are most 326 
affected.  327 
The main advantage of this explorative data driven approach is that it revealed clinical 328 
patterns that were quite unexpected and probably would have not been identified by 329 
a clinically driven approach. This is illustrated by two findings as examples: Firstly, the 330 
clinical dimension “mechanosensitivity” consisted of variables measuring 331 
mechanosensitivity at all muscle sites, not just over cervical or masticatory muscles. 332 
From the clinical point of view one might have expected two distinct dimensions, 333 
namely “cervical mechanosensitivity” and “masticatory mechanosensitivity”. However, 334 
due to the high correlation structure the analysis revealed that the two regions are 335 
highly interrelated with respect to mechanosensitivity and may not be seen as 336 
clinically different problems. On the one hand this finding confirms the fact that 337 
subjects with TMD suffer from referred pain into the neck region. On the other hand, 338 
this finding perhaps suggests that patients with TMD are dominated by mechanism(s) 339 
of central sensitization with associated areas of secondary hyperalgesia. 340 
A similar surprising result was seen for the variables NDI and CONTI which were found 341 
to occur together in one dimension. Even though it is known (25, 57–59) that these 342 
two variables are correlated, it was surprising that both variables were related so 343 
much to each other that they loaded equally highly on the same factor. From the 344 
clinical point of view one might have expected that the variable NDI would cluster 345 
together with variables measuring neck muscle mechanosensitivity or cervical ROM.  346 
Additionally, the CONTI might be expected to cluster together with jaw movements or 347 
variables measuring masticatory muscle mechanosensitivity .  348 
In this study, ROM of the upper cervical spine together with endurance of the neck 349 
flexors were not found to have any clinical relevance for any subgroup. (60) This is in 350 
contrast to previous studies showing evidence of altered upper cervical spine ROM and 351 
muscle performance in TMD overall and in specific sub-groups of people with TMD (16, 352 
59–61). The difference could be explained by the small sample size in some studies 353 
(60, 61), but that was not the case in the study by Armijo-Olivo and Magee (59). 354 
Further studies are required to elucidate this. 355 
Less surprising is that fact that the “Mixed“ group was the most affected group. One 356 
might expect this finding from the clinical point of view as well.  357 
A further advantage of the present study is the use of the extracted factors as 358 
summary variables of each identified clinical dimension. In that way a summary score 359 
of each clinical dimension could be calculated for each individual. As a consequence 360 
high/low individual scores mean large/low limitations in the respective dimension. The 361 
clinical relevance of this information requires careful consideration. These results 362 
confirm that patient’s with TMD are not homogenous, different subgroups exist with 363 
different clinical presentations. Each subgroup may therefore require a different form 364 
of intervention to address the underlying mechanisms.  365 
Clinical Implications  366 
The findings of this study have clinical implications for practice. In general there is a 367 
need to subgroup patients with TMD as they have distinct functional profiles with 368 
respect to the cervical and masticatory systems. Typically, this kind of procedure is 369 
conducted in daily clinical practice by therapists where individuals are categorized 370 
based on a comprehensive clinical evaluation in order to initialize individually tailored 371 
therapy and patient management programs (63). Similar broad-based evaluative 372 
approaches are undertaken in patients with low back pain (64). Furthermore it has 373 
been shown that sub-classification based therapy is more effective than standard 374 
protocols (65–68).  375 
The fact that NDI and CONTI are highly interrelated to form one clinical dimension 376 
suggests that when patients present with high levels of impairment of TMD, high levels 377 
of disability of the cervical region should also be expected. This holds true across all 378 
subgroups of TMD. As a consequence, management should address impaired domains 379 
detected by the NDI and CONTI. 380 
It would appear reasonable to suggest that for patients with arthrogenic and myogenic 381 
features of TMD, management should address mechanosensitivity of masticatory and 382 
neck muscles. However, the underlying pain mechanism in this dimension are 383 
indicative of central sensitization which requires a different management approach. 384 
Impaired mechanosensitivity seems to be less likely among patients with myogenic 385 
TMD and almost nonexistent in patients with arthrogenic TMD.    386 
Cervical ROM is another clinical dimension that seems to be problematic and needs 387 
attention in clinical practice in patients with „”Mixed“ TMD, but less so in myogenic 388 
and arthrogenic TMD.  In contrast, restricted ROM of the TMJ is similarly present 389 
across all TMD subgroups. 390 
In general, it can be noted that in none of the clinical dimensions does a single variable 391 
stand out that requires specific attention. For example, in the clinical dimension 392 
mechanosensitivity, there is not a single muscle alone that is affected. All muscles are 393 
equally affected. The same holds true for cervical ROM, where it is not a single 394 
movement but all planes that are equally affected.    395 
Strengths 396 
The strength of this paper is the application of factor analysis as an explorative data 397 
driven approach to characterize predefined subgroups with respect to until now 398 
unknown clinical patterns. This approach is unusual and not commonly applied. 399 
However, it has yielded unexpected but clinically meaningful and relevant implications. 400 
This was only possible due to a large sample size and detailed and extensive 401 
measurements which is uncommon in studies of TMD.   402 
However, there are other statistical approaches that perform subgroup classification 403 
based on data modelling. Common statistical techniques include among others cluster 404 
or latent class analysis. Instead of predefining subgroups based on clinical diagnosis 405 
these techniques create subgroups based on the observed data. Consequently, built 406 
classes are interpreted and analyzed with respect to clinical relevance (69).   407 
Limitations 408 
A potential weakness of this study is the exclusion of patients with chronic disease. As 409 
a result, it is not possible to draw any conclusions regarding those patients. 410 
Furthermore, this study did not include psychosocial aspects in the factor analysis. In 411 
addition, in an attempt to control for potential confounders it was not possible to use 412 
a matched case controlled design. Matched case controlled designs allow more 413 
efficient statistical analysis approaches resulting in more power. Finally, in order to 414 
disentangle the temporal relationship between onset of cervical spine and masticatory 415 
complaints, a longitudinal study designs is necessary.   416 
For the purpose of validation it is essential to replicate the study findings in further 417 
research. The presence of the identified clinical dimensions and patterns among 418 
subgroups of TMD need to be confirmed by confirmatory factor analysis in other 419 
samples. 420 
Conclusion 421 
An explorative data driven analysis was used for identifying clinical patterns among 422 
subgroups of TMD. These results have implications for clinical decision making and 423 
therapeutic management in patients with TMD. As a consequence, it is proposed that 424 
subgrouping patients with TMD is essential as these show distinctly different clinical 425 
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 643 
 644 
Table S1 online: Functional measurements of TMJ region and cervical spine 645 
Variables were used for identifying clinical patterns among TMD patients by explorative data analysis 646 
Measurements Description 
Conti Questionnaire Contains 10 questions that are related to problems originating 
from the temporomandibular region. Each question has three 
ranking options (0=none: 1=present: and 3=strong or 
bilateral). The likelihood of a CMD is divided into 4 subgroups: 
4- 9, none: 9-14, minimal: 15-21, moderate: 21-23, strong   
Colored Analogue Scale (CAS) Pain intensity scale similar to the visual analogue scale 
transformed in an increasing colored line in mm  that 
respresents the pain intensity  
Range of motion of TMJ Using a ruler of 15 cm, starting at 0, the active ROM of TMJ is 
measured including mouth opening, lateral shift, backward 
and forward movement of the jaw 
Mechanosensitivity of cervical 
and masticatory muscles 
The mechanical pressure pain threshold is assessed of the 
masticatory system and the neck mucles by a digital in 
kilogram force (Kgf). Muscles measured: Masseter, 
Temporalis, Upper Trapezius and Obliquus Capitis Inferior 
Neck Disability Index (NDI) A dimension-specific index that reflects “functional limitation” 
in neck disorders (includes 10 items (activities) with six 
different response options, ranging from “no disability” (0) to 
“complete disability.”(5) The total score is 50. A higher score 
indicates more pain and disability  
Cervical Range of Motion 
(CROM) 
 
Measurement of cervical spine flexion, extension, rotation and 
lateral flexion using an inclinometer 
Cranial cervical Flexion Test  
(CCFT) 
Measures the cervical flexor muscle synergy during upper 
cervical flexion. A pressure sensor positioned under the neck 
enables targeted increases in upper cervical flexion ROM by 
raising pressure in the sensor at 2 mm Hg increments from a 
baseline of 20, rising to 30mm Hg.  
Flexon Rotation Test (FRT) 
 
Passive rotation of the cervical spine in maximal flexion 
measured in supine. Subjective pain response and range of 
rotation is recorded. 
N° of cervical signs Palpation of the three upper cervical spine motion segments 
was to assess segmental mobility and pain. Score is sum of 
number of symptomatic findings.  
 647 












       
Female sex: 
n (%) 
11 (52%) 18(78%) 15 (84%) 15 (89%) 54 (83%) 0.045 
Age in years: 
mean (SD) 
33.15 (9.86) 32.61 (7.91) 35.11 (9.58) 31.11(8.55) 36 (13.61) 0.44 
CONTI: 
mean (SD) 




46.95 (5.47) 42.34 (4.45) 42.61 (6.91) 46.52 (5.11) 42.30 (6.65) 0.005 
 649 
 650 
Table 2: Factor loadings of measured variables 651 
The table shows contribution of each measured variable to each identified dimension by means of 652 
correlation coefficients. Grey shaded cells indicate high contribution. Based on correlation coefficients 653 
clinical characterization of dimensions is carried out. 654 

















MS trap right 0.88 -0.13 -0.15 0.12 -0.02 
MS trap left 0.83 -0.13 -0.28 0.03 -0.10 
MS obliq right 0.86 -0.08 -0.16 0.04 0.09 
MS obliq left 0.89 -0.04 -0.17 0.11 0.06 
MS temp right  0.85 0.02 -0.01 -0.03 -0.10 
MS temp left  0.85 0.06 -0.01 -0.03 0.02 
MS mass right 0.82 0.16 0.00 0.00 0.09 
MS mass left 0.80 0.12 0.06 0.07 0.10 
Nr° of cervical 
signs 
-0.64 -0.25 0.33 -0.14 -0.37 
Flexion -0.14 0.54 -0.05 0.18 0.04 
Extension 0.10 0.72 -0.13 0.11 0.05 
Lateralflex 
right 
0.12 0.77 -0.08 0.00 0.11 
Lateralflex left 0.08 0.80 -0.05 -0.10 0.08 
Rotation right -0.06 0.67 -0.13 0.13 0.05 
Rotation left -0.04 0.81 -0.08 0.13 0.10 
pain acute 0.07 -0.13 0.47 0.11 0.11 
NDI -0.21 -0.28 0.62 -0.10 0.16 
CONTI -0.28 -0.16 0.57 -0.24 0.21 
pain FRT right -0.18 0.02 0.72 -0.01 -0.42 
pain FRT left -0.25 -0.08 0.67 -0.10 -0.29 
mouth 
opening 
0.20 0.22 0.17 0.43 -0.06 
lateral shift left -0.04 -0.03 0.03 0.70 -0.01 
lateral shift 
right 
-0.09 0.10 -0.25 0.69 0.04 
Forward 
movement 
0.08 0.16 -0.02 0.67 -0.02 
Backward 
movement 
0.11 0.03 -0.06 0.45 0.11 
FRT ROM left 0.09 0.29 0.04 0.03 0.67 
FRT ROM right 0.01 0.02 -0.11 -0.05 0.78 
CCFT 
endurance 
-0.01 0.11 0.24 0.30 0.45 
 655 
 656 
Table 3: clinical pattern of subgroups is shown with respect to the cervical and masticatory systems. 657 
Legend table 3: Arrows indicate effects according to effect sizes. One arrow is a small effect, two arrows 658 
a medium effect and three arrows a large effect. 659 










Mixed ↓↓↓ ↓↓ ↓↓↓ ↓↓ - 
Myogen ↓ ↓ ↓↓↓ ↓↓ - 
Arthogen - - ↓↓↓ ↓↓ - 
Just signs - - - ↓↓ - 
 660 
  661 




 Title figure 2: Scores of all individuals on each of the five extracted factors representing clinical 663 
dimensions  664 
Legend figure 2: Black Cs represent the control group including the control group with symptoms of 665 
TMD (“Just signs”). Grey Ts represent the TMD group including the “Arthrogen”,”Myogen” and “Mixed” 666 
subgroup. Each plot shows scores of two dimension. E.g. the very left top plot depicts scores of 667 
dimension 1 on x-axis and scores of dimension 2 on y-axis Separation of dots with respect to group 668 
membership indicate distinct patterns.  669 
 670 
Title figure 3: Standardized mean differences of clinical dimensions between subgroups of TMD 671 
Legend figure 3: Differences (±95% Confidence Intervals) are shown between each of the subgroups to 672 
control group with respect to all clinical dimensions calculated by linear regression analysis. Factors 673 
representing a summary variable of each clinical dimension and single variables contributing to 674 
respective dimension are depicted. Results are to be interpreted as effect sizes (beta). Model is adjusted 675 
for age and gender where necessary.  676 
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